Intellipharmaceutics International Inc. (IPCI)

[fabius]

Why don't we get down to bottom line? EPS should give us an element for future company valuation.

Based on current products on the market we see analysts putting out a 12m forward EPS of 0.4.

Let's cut it in half for a conservative scenario.
Then let's pick the s&p AVG p/e of 18. (P/e for biotechs is much more)
Shares count @ 31mln.

We should get 6 $, 12months price target.

This without further Andas, no partnership, no Rexista.

Let's reduce it for contingencies by 1/3. 4$

At the end of the day, this is a very basic scenario. But it is a numeric case, very conservative, for the long investor.
No speculative component essentially

I explicitly wanted to be as basic as possible